Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade B 45.31 0.33% 0.15
URGN closed up 0.33 percent on Monday, December 10, 2018, on 82 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical URGN trend table...

Date Alert Name Type % Chg
Dec 10 50 DMA Support Bullish 0.00%
Dec 10 Lower Bollinger Band Touch Weakness 0.00%
Dec 7 20 DMA Resistance Bearish 0.33%
Dec 7 Crossed Above 50 DMA Bullish 0.33%
Dec 6 Fell Below 50 DMA Bearish 1.03%
Dec 6 Expansion Pivot Sell Setup Bearish Swing Setup 1.03%
Dec 6 Hammer Candlestick Bullish 1.03%
Dec 6 Lizard Bullish Bullish Day Trade Setup 1.03%
Dec 6 Down 3 Days in a Row Weakness 1.03%
Dec 6 Lower Bollinger Band Touch Weakness 1.03%

Older signals for URGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.57
52 Week Low 36.66
Average Volume 67,932
200-Day Moving Average 50.7539
50-Day Moving Average 45.0336
20-Day Moving Average 47.2405
10-Day Moving Average 47.318
Average True Range 3.1088
ADX 17.7
+DI 15.9107
-DI 31.4071
Chandelier Exit (Long, 3 ATRs ) 41.6636
Chandelier Exit (Short, 3 ATRs ) 49.9364
Upper Bollinger Band 51.0095
Lower Bollinger Band 43.4715
Percent B (%b) 0.24
BandWidth 15.956647
MACD Line 0.3081
MACD Signal Line 0.8362
MACD Histogram -0.5281
Fundamentals Value
Market Cap 589.44 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -27.13
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.01
Resistance 3 (R3) 51.47 48.71 50.89
Resistance 2 (R2) 48.71 47.00 48.98 50.52
Resistance 1 (R1) 47.01 45.95 47.86 47.54 50.15
Pivot Point 44.25 44.25 44.67 44.51 44.25
Support 1 (S1) 42.55 42.54 43.40 43.08 40.47
Support 2 (S2) 39.78 41.49 40.05 40.10
Support 3 (S3) 38.08 39.78 39.73
Support 4 (S4) 38.61